Bayesian Capital Management, LP Vertex Pharmaceuticals Inc Transaction History

Bayesian Capital Management, LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $1.19 Million - $1.31 Million	2,931 New	2,931 $1.23 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $2.59 Million - $2.95 Million	9,131 New	9,131 $2.88 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $1.85 Million - $2.3 Million	-7,869 Reduced 81.12%	1,831 $516,000
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $1.45 Million - $1.71 Million	6,560 Added 208.92%	9,700 $2.53 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $555,811 - $701,633	3,140 New	3,140 $690,000
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $1.26 Million - $1.47 Million	-6,100 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $1.08 Million - $1.44 Million	-5,222 Reduced 46.12%	6,100 $1.44 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $2.89 Million - $3.43 Million	11,322 New	11,322 $3.08 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $1.16 Million - $1.44 Million	-5,800 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $718,186 - $964,604	4,308 Added 288.74%	5,800 $1.27 Million
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $248,015 - $279,138	1,492 New	1,492 $253,000
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $2.75 Million - $3.16 Million	-16,421 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $2.02 Million - $2.35 Million	13,839 Added 535.98%	16,421 $2.79 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $391,431 - $457,349	2,582 New	2,582 $421,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.